Exact Mass: 451.1923008
Exact Mass Matches: 451.1923008
Found 93 metabolites which its exact mass value is equals to given mass value 451.1923008,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Doxazosin
Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Piscerythramine
C26H29NO6 (451.19947740000003)
A hydroxyisoflavone that is isoflavone substituted by hydroxy groups at positions 5, 7 and 3, prenyl groups at positions 2 and 6, a methoxy group at position 5 and an amino group at position 4.
4-Hydroxypropranolol glucuronide
C22H29NO9 (451.18422240000007)
tetrahydrogeranylgeranyl-PP
Tetrahydrogeranylgeranyl-pp is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Tetrahydrogeranylgeranyl-pp can be found in a number of food items such as muskmelon, wax gourd, deerberry, and pineapple, which makes tetrahydrogeranylgeranyl-pp a potential biomarker for the consumption of these food products.
Isopiscerythramine
C26H29NO6 (451.19947740000003)
Pseudolycorine-1-O-beta-D-glucoside
C22H29NO9 (451.18422240000007)
9beta,2-dihydroxy-4,5-dimethoxy-lythran-12-one|9beta-hydroxyvertine
C26H29NO6 (451.19947740000003)
doxazosin
C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 3293
Ala Cys Lys Met
Ala Cys Met Lys
Ala Lys Cys Met
Ala Lys Met Cys
Ala Met Cys Lys
Ala Met Lys Cys
Cys Ala Lys Met
Cys Ala Met Lys
Cys Cys Lys Val
Cys Cys Val Lys
Cys Lys Ala Met
Cys Lys Cys Val
Cys Lys Met Ala
Cys Lys Val Cys
Cys Met Ala Lys
Cys Met Lys Ala
Cys Arg Ser Ser
C15H29N7O7S (451.18490840000004)
Cys Ser Arg Ser
C15H29N7O7S (451.18490840000004)
Cys Ser Ser Arg
C15H29N7O7S (451.18490840000004)
Cys Val Cys Lys
Cys Val Lys Cys
Lys Ala Cys Met
Lys Ala Met Cys
Lys Cys Ala Met
Lys Cys Cys Val
Lys Cys Met Ala
Lys Cys Val Cys
Lys Met Ala Cys
Lys Met Cys Ala
Lys Val Cys Cys
Met Ala Cys Lys
Met Ala Lys Cys
Met Cys Ala Lys
Met Cys Lys Ala
Met Lys Ala Cys
Met Lys Cys Ala
Arg Cys Ser Ser
C15H29N7O7S (451.18490840000004)
Arg Ser Cys Ser
C15H29N7O7S (451.18490840000004)
Arg Ser Ser Cys
C15H29N7O7S (451.18490840000004)
Ser Cys Arg Ser
C15H29N7O7S (451.18490840000004)
Ser Cys Ser Arg
C15H29N7O7S (451.18490840000004)
Ser Arg Cys Ser
C15H29N7O7S (451.18490840000004)
Ser Arg Ser Cys
C15H29N7O7S (451.18490840000004)
Ser Ser Cys Arg
C15H29N7O7S (451.18490840000004)
Ser Ser Arg Cys
C15H29N7O7S (451.18490840000004)
Val Cys Cys Lys
Val Cys Lys Cys
Val Lys Cys Cys
4-methylumbelliferyl a-l-idopyranosiduronic acid, cyclohexylammonium salt
C22H29NO9 (451.18422240000007)
AZ 628
AZ 628 is a pan-Raf kinase inhibitor with IC50s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and c-Raf-1, respectively.
(1r)-1-[(4-{[(6,7-Dihydro[1,4]dioxino[2,3-C]pyridazin-3-Yl)methyl]amino}piperidin-1-Yl)methyl]-9-Fluoro-1,2-Dihydro-4h-Pyrrolo[3,2,1-Ij]quinolin-4-One
C24H26FN5O3 (451.20195780000006)
Dihydrocodeine bitartrate
C22H29NO9 (451.18422240000007)
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
Homofenazine
C23H28F3N3OS (451.19050740000006)
C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic
[oxido-[(2E)-3,7,11,15-tetramethylhexadeca-2,14-dienoxy]phosphoryl] phosphate
7-{2-Hydroxy-3-[(naphthalen-1-yl)oxy]propyl}-3-methyl-8-(morpholin-4-yl)-3,7-dihydropurine-2,6-dione
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide
C20H29N5O5S (451.18893040000006)
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide
C20H29N5O5S (451.18893040000006)
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide
C20H29N5O5S (451.18893040000006)
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide
C20H29N5O5S (451.18893040000006)
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide
C20H29N5O5S (451.18893040000006)
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide
C20H29N5O5S (451.18893040000006)
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide
C20H29N5O5S (451.18893040000006)
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide
C20H29N5O5S (451.18893040000006)
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1-methyl-4-imidazolesulfonamide
C20H29N5O5S (451.18893040000006)
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide
C20H29N5O5S (451.18893040000006)
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-1-methyl-4-imidazolesulfonamide
C20H29N5O5S (451.18893040000006)
(5Z)-5-[(1-Benzyl-3,4-dihydro-2H-quinolin-6-yl)methylidene]-1-(2-methylphenyl)-1,3-diazinane-2,4,6-trione
AZ304
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM). Anti-tumor activity[1].
9,20-dihydroxy-4,5-dimethoxy-16-oxa-24-azapentacyclo[15.7.1.1⁸,¹².0²,⁷.0¹⁹,²⁴]hexacosa-2(7),3,5,8(26),9,11,13-heptaen-15-one
C26H29NO6 (451.19947740000003)
(2r,3s,4s,5r,6s)-2-{[(1r,14s,15s,16s)-4,14-dihydroxy-5-methoxy-9-azatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-2(7),3,5,12-tetraen-15-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
C22H29NO9 (451.18422240000007)
methyl (2s,3s,5s,6r,10s)-5-hydroxy-2,6-dimethyl-21-oxo-3-(2-oxopropyl)-14-oxa-8-azahexacyclo[11.6.1.1⁵,¹⁹.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-1(19),13(20),15,17-tetraene-18-carboxylate
C26H29NO6 (451.19947740000003)
(2s,4r)-2-hydroxy-2,4-dimethyl-4-[(1e)-2-[(3s,4s)-2,4,5-trihydroxy-3-methoxy-4-phenyl-3h-quinolin-6-yl]ethenyl]cyclohexan-1-one
C26H29NO6 (451.19947740000003)
3-[4-amino-3-hydroxy-5-methoxy-2-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-8-(3-methylbut-2-en-1-yl)chromen-4-one
C26H29NO6 (451.19947740000003)
(1s,13z,17r,19s,20r)-9,20-dihydroxy-4,5-dimethoxy-16-oxa-24-azapentacyclo[15.7.1.1⁸,¹².0²,⁷.0¹⁹,²⁴]hexacosa-2(7),3,5,8(26),9,11,13-heptaen-15-one
C26H29NO6 (451.19947740000003)
18-(furan-3-yl)-10-hydroxy-4,9,9,19-tetramethyl-5,17-dioxa-2-azapentacyclo[11.8.0.0³,¹¹.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,11-triene-6,16-dione
C26H29NO6 (451.19947740000003)
methyl (2s,5s,6r,10s)-5-hydroxy-2,6-dimethyl-21-oxo-3-(2-oxopropyl)-14-oxa-8-azahexacyclo[11.6.1.1⁵,¹⁹.0²,¹⁰.0³,⁸.0¹⁷,²⁰]henicosa-1(19),13(20),15,17-tetraene-18-carboxylate
C26H29NO6 (451.19947740000003)
(4s,8s,10r,14s,18r,19r)-18-(furan-3-yl)-10-hydroxy-4,9,9,19-tetramethyl-5,17-dioxa-2-azapentacyclo[11.8.0.0³,¹¹.0⁴,⁸.0¹⁴,¹⁹]henicosa-1(13),2,11-triene-6,16-dione
C26H29NO6 (451.19947740000003)